We have developed a patented proprietary method of extracting various cannabinoids from the marijuana plant and converting them into products with a higher level of quality and consistency.
We have developed a proprietary method of extracting cannabinoids from cannabis plants and converting the resulting cannabinoid extracts into concentrates such as oils, waxes, edibles and shatter. These concentrates may be ingested in a number of ways, including through vaporization via electronic cigarettes and used for a variety of pharmaceutical and other purposes. CLS Holdings has recently received a patent from the U.S. Patent Office for its proprietary extraction and conversion methodology.
Ray Keller, a shareholder of CLS, and a founder of CLS Labs developed this process for extracting, cleaning and converting cannabinoids from cannabis plants. He has also created various delivery systems and materials to ready the converted cannabis product for different uses by different potential distributors. We believe that this proprietary process will allow us to extract and convert cannabinoids in a greater yield than methods currently used in the industry. We believe this proprietary process and the ability to manufacture these refined cannabinoids into products that can be used in multiple delivery systems will provide us with a strategic advantage in the cannabis industry.
We believe we can produce a much larger amount of Delta-9 THC from plants compared to competitors, resulting in higher revenues.
We plan to provide one-stop, multi-state services to companies wishing to build private label brands that deliver consistent products.
Our technology can produce cleaner and safer products as a result of advanced testing.